Intuitive Surgical, Inc. (NASDAQ:ISRG) Holdings Boosted by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 65.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,913 shares of the medical equipment provider's stock after buying an additional 755 shares during the period. Thurston Springer Miller Herd & Titak Inc.'s holdings in Intuitive Surgical were worth $998,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Hazlett Burt & Watson Inc. raised its holdings in Intuitive Surgical by 5.8% in the third quarter. Hazlett Burt & Watson Inc. now owns 362 shares of the medical equipment provider's stock valued at $177,000 after acquiring an additional 20 shares in the last quarter. Mitchell Mcleod Pugh & Williams Inc. raised its stake in shares of Intuitive Surgical by 4.1% in the 3rd quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 503 shares of the medical equipment provider's stock valued at $247,000 after purchasing an additional 20 shares in the last quarter. Fragasso Financial Advisors Inc lifted its position in shares of Intuitive Surgical by 3.0% during the fourth quarter. Fragasso Financial Advisors Inc now owns 687 shares of the medical equipment provider's stock worth $359,000 after purchasing an additional 20 shares during the last quarter. Ullmann Wealth Partners Group LLC grew its stake in Intuitive Surgical by 1.6% in the third quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider's stock worth $653,000 after purchasing an additional 21 shares in the last quarter. Finally, Meeder Advisory Services Inc. increased its holdings in Intuitive Surgical by 0.3% in the third quarter. Meeder Advisory Services Inc. now owns 7,386 shares of the medical equipment provider's stock valued at $3,629,000 after buying an additional 22 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Brian Edward Miller sold 2,553 shares of the company's stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $515.00, for a total value of $1,314,795.00. Following the transaction, the executive vice president now owns 7,066 shares of the company's stock, valued at approximately $3,638,990. This represents a 26.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 2,128 shares of the firm's stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $515.00, for a total value of $1,095,920.00. Following the sale, the senior vice president now directly owns 273 shares of the company's stock, valued at approximately $140,595. This represents a 88.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 48,190 shares of company stock valued at $25,012,927. 0.80% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Erste Group Bank upgraded Intuitive Surgical from a "hold" rating to a "buy" rating in a report on Tuesday, November 19th. Citigroup increased their target price on shares of Intuitive Surgical from $567.00 to $640.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Morgan Stanley raised shares of Intuitive Surgical from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $522.00 to $650.00 in a report on Monday, December 2nd. Raymond James raised their target price on shares of Intuitive Surgical from $500.00 to $540.00 and gave the stock an "outperform" rating in a report on Monday, October 14th. Finally, Stifel Nicolaus increased their price target on Intuitive Surgical from $525.00 to $610.00 and gave the stock a "buy" rating in a research report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $554.17.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG traded up $3.97 during mid-day trading on Thursday, reaching $584.08. 2,119,290 shares of the company traded hands, compared to its average volume of 1,655,838. Intuitive Surgical, Inc. has a fifty-two week low of $355.17 and a fifty-two week high of $585.50. The firm has a market cap of $208.04 billion, a PE ratio of 93.90, a price-to-earnings-growth ratio of 4.66 and a beta of 1.39. The stock has a fifty day simple moving average of $538.34 and a 200-day simple moving average of $497.08.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The business had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. As a group, analysts predict that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.